Abstract Number: 320 • ACR/ARHP Annual Meeting 2017
Teriparatide Compared with Risedronate and the Risk of Clinical Vertebral Fractures: 2-Year Results of a Randomized, Double-Dummy Clinical Trial
Background/Purpose: The VERO trial was an active-controlled fracture endpoint clinical trial that recruited postmenopausal women with low bone mass and prevalent vertebral fractures (VFx). We…Abstract Number: 349 • ACR/ARHP Annual Meeting 2016
Effects of Osteoporosis Treatments for Bone Loss and Pain-Related Behavior in the Hind Limb-Unloaded Mouse Model of Disuse Osteoporosis
Background/Purpose: Osteoporotic patients with no evidence of fractures sometimes experience vague lower back pain. However, there have been few reports regarding the correlation between…Abstract Number: 353 • ACR/ARHP Annual Meeting 2015
A Longitudinal Cohort Study of Weekly Teriparatide, Denosmab, and Bisphosphonates for Prevention of Vertebral Fractures in Glucocorticoid-Induced Osteoporosis
Background/Purpose: Although weekly teriparatide (56.5ug, wTPTD) and denosmab (DMAB) have been developed as potent anti-osteoporotic agents, effects of these agents on prevention of osteoporotic fractures…Abstract Number: 357 • ACR/ARHP Annual Meeting 2015
Human Parathyroid Hormone for Preventing and Treating Glucocorticoid-Induced Osteoporosis: Cochrane Systematic Review and Meta-Analysis
Background/Purpose: Although glucocorticoid-induced osteoporosis is the most common cause of secondary osteoporosis, providing effective treatment remains a challenge. Bisphosphonates are currently recommended for treatment and…
ACR Meeting Abstracts